Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 11, 2009Clinical Cancer Research

Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJurjen S. LagasRWRobert A.B. van WaterschootVTVicky A.C.J. van Tilburg

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lagas et al. (2009) studied this question.

synapsesocial.com/papers/6a73dcefc553859489f161a2https://doi.org/10.1158/1078-0432.ccr-08-2253
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Meningeal carcinomatosis in small cell carcinoma of the lung1982 · 15 citations
  2. 2Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study2007 · 369 citations
  3. 3Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy2006 · 611 citations
  4. 4The Effect of Bcrp1 (Abcg2) on the <i>In vivo</i> Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients2005 · 351 citations
  5. 5Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase2007 · 374 citations